- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07650240
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial (SPARKLE)
A Phase II Randomized Trial of Intermittent Androgen Deprivation Therapy Alone or Combined With [177Lu]Lu-PSMA-617, With or Without Abiraterone and Prednisone, in Patients With Low-Volume Metastatic Hormone-Sensitive Prostate Cancer
This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited number of anatomic sites at the time of initial diagnosis (de novo low volume metastasis) or that has come back after a period of improvement (recurrent). Standard of care treatment for prostate cancer usually includes androgen deprivation therapy, with or without abiraterone acetate and prednisone. Leuprolide acetate is a form of androgen deprivation therapy. It blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. 177Lu-PSMA-617 is a type of radioconjugate drug. Upon administration, vipivotide tetraxetan targets and binds to prostate specific membrane antigen (PSMA)-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is overexpressed on prostate tumor cells. Abiraterone acetate is a type of anti-androgen drug. It blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of cancer cells that need androgens to grow. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving 177Lu-PSMA-617 in combination with leuprolide acetate, with or without abiraterone acetate and prednisone, may be more effective at treating patients with recurrent or de novo low volume metastatic hormone-sensitive prostate cancer than giving leuprolide acetate alone.
Studienübersicht
Status
Bedingungen
- Prostatakrebs
- Metastasierter Prostatakrebs
- Prostata-Adenokarzinom
- Fortgeschrittener Prostatakrebs
- Lokalisiertes Prostatakarzinom
- Stadium IVB Prostatakrebs AJCC v8
- Adenokarzinom der Prostata
- Metastasierendes Prostata-Adenokarzinom
- Fortgeschrittenes Prostata-Adenokarzinom
- Rezidivierendes Prostata-Adenokarzinom
- Kastrationsempfindlicher Prostatakrebs
- Metastasierter hormonsensitiver Prostatakrebs (mHSPC)
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
Studieren Sie die Kontaktsicherung
- Name: Urology Study Coordinator
- Telefonnummer: 507-422-5076
Studienorte
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic in Rochester
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
-
Kontakt:
- Urology Study Coordinator
- Telefonnummer: 507-422-5076
-
Hauptermittler:
- Matthew K. Tollefson, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Male patients aged 18 years or older
-
Signed informed consent must be obtained prior to participation in the study
-
Histologically confirmed adenocarcinoma of the prostate
-
Prior treatment with radical prostatectomy or radiation therapy for localized disease is required
-
Prior treatment with ADT or androgen receptor pathway inhibitor (ARPI) or cytotoxic chemotherapy is permitted if:
- The last treatment > 12 months from enrollment on the trial
- The duration of treatment is less than 3 months and no evidence of disease progression on treatment
-
Disease detected on PSMA PET/CT scan [PSMA-avid low volume metastasis (LVM)]. Patients with standardized uptake value maximum (SUVMax) lesion/liver >1 [molecular imaging PSMA (miPSMA) score of 2] or lesion/parotid > 1 (miPSMA score of 3) would be included. PET scanners used in the study will comply with current guidelines established by the European Association of Nuclear Medicine (EANM) Research Limited (Ltd) (EARL) for harmonizing PET/CT image acquisition and reconstruction
-
Patients with hormone sensitive low volume metastatic disease (LVM); either de novo metastatic or recurrent disease. LVM, as assessed on PSMA PET/CT is defined as:
-
=< 10 total metastatic spots
- Lymph nodes with short axis of =< 2.5 cm
- Total tumor volume (TTV) < 200 mL
-
=< 4 bone metastases
-
No brain or liver metastases
-
-
Eastern Cooperative Oncology Group (ECOG) performance 0 - 2
-
Hemoglobin >= 9 g/dL
-
Platelet count >= 100,000/mm^3
-
Absolute neutrophil count >= 1,500/mm^3
-
Serum bilirubin =< 1.5 x upper limit of normal (ULN)
-
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x ULN
-
Serum creatinine =< 1.5 x ULN or an estimated glomerular filtration rate (eGFR) >= 50 mL/min/1.73m^2
-
Able to start therapy within 28 days of screening
-
Expected life expectancy > 6 months
Exclusion Criteria:
-
PSMA-undetectable disease defined as rising prostate specific antigen (PSA) with absence of PSMA-positive lesions in PSMA PET/CT imaging
-
PSMA-negative disease defined as lesions detected on imaging that are deemed concerning for active cancer metastasis with PSMA SUVmax less than liver and meeting specific size criteria: lymph nodes with short axis of >= 2.5 cm, visceral lesions with a solid appearance (soft tissue density) >= 1 cm, and bone metastases with a measurable soft tissue component >= 1 cm
-
Patient with in-field failure (disease recurrence in prostate bed after primary definitive prostatectomy or radiotherapy)
-
Patient with spinal metastatic disease-causing cord compression
-
Patient with prior disease progression on ADT [castration resistance prostate cancer (CRPC)]
-
Prior treatment with ADT or cytotoxic chemotherapy or ARPI within less than 12 months from enrollment on the trial
-
Prior treatment with ADT or ARPI or cytotoxic chemotherapy is permitted only if more than 3 months treatment duration and no evidence of disease progression on treatment
-
Patients with severe [Common Terminology Criteria for Adverse Events (CTCAE) grade > 2] xerostomia
-
Patients with well documented history of myelosuppression or renal disease that might impair their participation in the trial per medical advice
-
Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible
-
Estimated life expectancy < 6 months
-
Concurrent serious medical co-morbidities as determined by study investigator and expected to impair participation in the study
- Subjects with female partners of reproductive potential are required to use effective, medically acceptable methods of birth control (e.g., spermicide in conjunction with a barrier such as a condom or sexual abstinence) while on this study, and for 14 weeks after the last dose of 177Lu-PSMA-617
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm A1 (177Lu-PSMA-617, iADT)
Patients receive 177Lu-PSMA-617 IV once every 6 weeks and leuprolide acetate subcutaneous (SC) once every 3 months (Q3M). Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial and undergo SPECT on study. |
Ancillary studies
Andere Namen:
Undergo collection of blood samples
Andere Namen:
Given IV
Andere Namen:
Given SC
Andere Namen:
Undergo PSMA PET/CT
Andere Namen:
Undergo SPECT
Andere Namen:
|
|
Aktiver Komparator: Arm A2 (iADT)
Patients receive leuprolide acetate SC Q3M for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial. |
Ancillary studies
Andere Namen:
Undergo collection of blood samples
Andere Namen:
Given SC
Andere Namen:
Undergo PSMA PET/CT
Andere Namen:
|
|
Experimental: Arm B1 (177Lu-PSMA-617, iADT, iAA, P)
Patients receive 177Lu-PSMA-617 IV every 6 weeks, leuprolide acetate SC Q3M, abiraterone acetate PO (by mouth) QD (once a day) and prednisone PO BID (twice a day). Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial and undergo SPECT on study. |
Ancillary studies
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood samples
Andere Namen:
Given PO
Andere Namen:
Given IV
Andere Namen:
Given SC
Andere Namen:
Undergo PSMA PET/CT
Andere Namen:
Undergo SPECT
Andere Namen:
|
|
Aktiver Komparator: Arm B2 (iADT, iAA, P)
Patients receive leuprolide acetate SC Q3M, abiraterone acetate PO QD and prednisone PO BID. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial. |
Ancillary studies
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood samples
Andere Namen:
Given PO
Andere Namen:
Given SC
Andere Namen:
Undergo PSMA PET/CT
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Radiographic progression free survival (rPFS)
Zeitfenster: At 18 months
|
Will be evaluated according to prostate specific membrane antigen (PSMA) positron emission tomography (PET) progression (PPP) criteria. Defined as the time from enrollment to documented radiographic progression or death from any cause, whichever occurs first. |
At 18 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Biochemical recurrence free survival (BCR-FS)
Zeitfenster: At 12 months
|
Assessed using PSMA scans. Defined as the time after treatment during which no signs of biochemical recurrence are found. |
At 12 months
|
|
Treatment-free interval
Zeitfenster: Up to 18 months
|
Defined as the length of time a patient remains off active systemic therapies while maintaining disease control. |
Up to 18 months
|
|
Overall survival
Zeitfenster: Up to 3 years
|
Defined as the time from randomization or enrollment to death from any cause, whichever occurs first. |
Up to 3 years
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Quality of life - FACT-P
Zeitfenster: At baseline and then every 3 months up to 1 year
|
Assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire, a 39-item questionnaire used to measures Health-Related Quality of Life (HRQOL) in prostate cancer patients. Responses to each question are scored on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Possible total scores range from 0-156, with higher scores indicating better QoL. A drop in the FACT-P total score >5 points will be considered clinically meaningful. |
At baseline and then every 3 months up to 1 year
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Matthew K. Tollefson, MD, Mayo Clinic in Rochester
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Genitale Neubildungen, männlich
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Genitalerkrankungen, männlich
- Prostataerkrankungen
- Männliche Urogenitalerkrankungen
- Prostataneoplasmen
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Hypophysenhormon-Freisetzungshormone
- Hypothalamische Hormone
- Peptidhormone
- Neuropeptide
- Peptide
- Aminosäuren, Peptide und Proteine
- Oligopeptide
- Nervengewebeproteine
- Proteine
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Physikalische Phänomene
- Polycyclische Verbindungen
- Schwangerschaft
- Schwangerschaft
- Steroide
- Fusions-Ring-Verbindungen
- Schwangerschaften
- Elektromagnetische Phänomene
- Magnetische Phänomene
- Androstenes
- Androstanes
- Elektromagnetische Strahlung
- Strahlung
- Strahlung, ionisieren
- Elementarpartikel
- Licht
- Optische Phänomene
- Strahlung, nichtionisierend
- Gonadotropin-freisetzendes Hormon
- Abirateronacetat
- Pluvicto
- Prednison
- Leuprolid
- Luprolid -Acetat -Gel -Depot
- Handhabung von Proben
- Röntgenaufnahmen
- Photonen
- Deltacortene
- Prednyliden
Andere Studien-ID-Nummern
- MC250507
- 25-008953 (Andere Kennung: Mayo Clinic Institutional Review Board)
- SPARKLE (Andere Kennung: Mayo Clinic Urology)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .